Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Diaphragmatic Surgery and Related Complications In Primary Cytoreduction for Advanced Ovarian, Tubal, and Peritoneal Carcinoma.

Ye S, He T, Liang S, Chen X, Wu X, Yang H, Xiang L.

BMC Cancer. 2017 May 5;17(1):317. doi: 10.1186/s12885-017-3311-8.

2.

A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS.

Gynecol Oncol. 2017 Apr;145(1):27-31. doi: 10.1016/j.ygyno.2017.02.020. Epub 2017 Feb 14.

PMID:
28209497
3.

Cardiophrenic lymph node metastasis in low-grade serous ovarian adenocarcinoma.

Serna-Gallegos T, Gallegos N, Bristow RE.

Gynecol Oncol Rep. 2016 Dec 14;19:31-33. doi: 10.1016/j.gore.2016.12.001. eCollection 2017 Feb.

4.

In Pursuit of Optimal Cytoreduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon.

Shashikant L, Kesterson Joshua P.

J Obstet Gynaecol India. 2009 May-Jun;59(3):209-216.

5.

Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.

Garcia-Soto AE, Java JJ, Nieves Neira W, Pearson JM, Cohn DE, Lele SB, Tewari KS, Walker JL, Alvarez Secord A, Armstrong DK, Copeland LJ.

Gynecol Oncol. 2016 Dec;143(3):484-489. doi: 10.1016/j.ygyno.2016.10.003. Epub 2016 Oct 7.

PMID:
27726923
6.

Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012.

Kim SI, Lim MC, Lim J, Won YJ, Seo SS, Kang S, Park SY.

J Gynecol Oncol. 2016 Jan;27(1):e5. doi: 10.3802/jgo.2016.27.e5. Epub 2015 Dec 1.

7.

A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery.

Barber EL, Rutstein S, Miller WC, Gehrig PA.

Gynecol Oncol. 2015 Dec;139(3):401-6. doi: 10.1016/j.ygyno.2015.09.080. Epub 2015 Oct 23.

8.

Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study.

Ren Y, Jiang R, Yin S, You C, Liu D, Cheng X, Tang J, Zang R.

BMC Cancer. 2015 Aug 13;15:583. doi: 10.1186/s12885-015-1525-1.

9.

Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.

Suidan RS, Leitao MM Jr, Zivanovic O, Gardner GJ, Long Roche KC, Sonoda Y, Levine DA, Jewell EL, Brown CL, Abu-Rustum NR, Charlson ME, Chi DS.

Gynecol Oncol. 2015 Aug;138(2):246-51. doi: 10.1016/j.ygyno.2015.05.034. Epub 2015 May 31.

10.

Risk stratification and outcomes of women undergoing surgery for ovarian cancer.

Patankar S, Burke WM, Hou JY, Tergas AI, Huang Y, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Gynecol Oncol. 2015 Jul;138(1):62-9. doi: 10.1016/j.ygyno.2015.04.037. Epub 2015 May 11.

11.

Quality of life and sexuality comparison between sexually active ovarian cancer survivors and healthy women.

Kim SI, Lee Y, Lim MC, Joo J, Park K, Lee DO, Park SY.

J Gynecol Oncol. 2015 Apr;26(2):148-54. doi: 10.3802/jgo.2015.26.2.148. Epub 2015 Jan 26.

12.

Comparative effectiveness research in gynecologic oncology.

Patankar S, Tergas AI, Wright JD.

Cancer Treat Res. 2015;164:237-59. doi: 10.1007/978-3-319-12553-4_13.

13.

Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.

Suidan RS, Zhou Q, Iasonos A, O'Cearbhaill RE, Chi DS, Long Roche KC, Tanner EJ, Denesopolis J, Barakat RR, Zivanovic O.

Int J Gynecol Cancer. 2015 May;25(4):599-606. doi: 10.1097/IGC.0000000000000389.

14.

Targeting those with decreased meaning and peace: a supportive care opportunity.

Brown AJ, Sun CC, Urbauer D, Zhukovsky DS, Levenback C, Frumovitz M, Thaker PH, Bodurka DC, Ramondetta LM.

Support Care Cancer. 2015 Jul;23(7):2025-32. doi: 10.1007/s00520-014-2568-6. Epub 2014 Dec 18.

15.

Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients.

Brown AJ, Sun CC, Prescott LS, Taylor JS, Ramondetta LM, Bodurka DC.

Gynecol Oncol. 2014 Nov;135(2):244-8. doi: 10.1016/j.ygyno.2014.08.039. Epub 2014 Sep 2.

16.

A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Mironov S, Iyer RB, Zhou Q, Iasonos A, Paul H, Hosaka M, Aghajanian CA, Leitao MM Jr, Gardner GJ, Abu-Rustum NR, Sonoda Y, Levine DA, Hricak H, Chi DS.

Gynecol Oncol. 2014 Sep;134(3):455-61. doi: 10.1016/j.ygyno.2014.07.002. Epub 2014 Jul 11.

17.

Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review).

Dogan NU, Schneider A, Chiantera V, Dogan S, Dursun P.

Oncol Lett. 2013 Sep;6(3):642-647. Epub 2013 Jul 4.

18.

Intrathoracic gastric volvulus as a severe, delayed surgical complication after left subphrenic peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian cancer.

Caronna R, Sammartino P, Framarino ML, Sollazzo BM, Meniconi RL, Chirletti P.

World J Surg Oncol. 2013 Sep 23;11:239. doi: 10.1186/1477-7819-11-239.

19.

TNFAIP8 as a predictor of metastasis and a novel prognostic biomarker in patients with epithelial ovarian cancer.

Liu T, Gao H, Chen X, Lou G, Gu L, Yang M, Xia B, Yin H.

Br J Cancer. 2013 Sep 17;109(6):1685-92. doi: 10.1038/bjc.2013.501. Epub 2013 Aug 27.

20.

Advanced ovarian cancer: what should be the standard of care?

Goff BA.

J Gynecol Oncol. 2013 Jan;24(1):83-91. doi: 10.3802/jgo.2013.24.1.83. Epub 2013 Jan 8.

Supplemental Content

Support Center